Lumbar disc degeneration severity on magnetic resonance imaging (MRI) is associated with low back pain. Proinflammatory chemokines CCL5 and CXCL6 are released by induced degenerative discs, and CCL5 has been associated with discogenic back pain. A case-control study was performed, based on the Hong Kong Disc Degeneration Population-Based Cohort of Southern Chinese, to investigate if systemic levels of CCL5 and CXCL6 were elevated in subjects with disc degeneration compared to non-degenerated individuals. Eighty subjects were selected, 40 with no disc degeneration (control group; DDD score 0) and 40 with moderate/severe disc degeneration (disc degeneration group; DDD score ≥5) as noted on MRI. Subjects were matched for age, sex, body mass index and workload. Blood plasma samples were obtained from each individual, and levels of CCL5 and CXCL6 were measured. Secondary phenotypes of lumbar disc displacement and cervical disc changes were also assessed. CCL5 concentrations were significantly increased in the disc degeneration (mean: 19.8 ng/mL) compared to the control group (mean: 12.8 ng/mL) (p = 0.015). The degeneration group demonstrated higher levels of CXCL6 (mean: 56.9 pg/mL) compared to the control group (mean: 43.4 pg/mL) (p = 0.010). There was a trend towards elevated CCL5 levels with disc displacement in the degeneration group (p = 0.073). Cervical disc degeneration was not associated with elevated chemokine levels (p > 0.05). This is the first study to note that elevated systemic CCL5 and CXCL6 were associated with moderate/severe lumbar disc degeneration, further corroborating tissue studies of painful discs. These chemokines may be systemic biomarkers for the diagnosis and monitoring of disc degeneration.
Introduction
Low back pain (LBP) is the world's most disabling condition (Vos et al., 2012) , representing a substantial socioeconomic and health-care burden (Dagenais et al., 2008) . Although the aetiology of LBP is multifactorial, intervertebral disc degeneration has been noted to be a determinant (Andersson, 1999; Shen et al., 2006) . However, diagnostics of discogenic-related LBP can be tenuous and previous methods, such as discography, are questionable and may have complications (Carragee et al., 2009) .
Magnetic resonance imaging (MRI) is a non-invasive modality that allows assessment of the soft tissue structures of the spine, in particular the disc that may otherwise be undetected using x-rays. Previous studies have noted that a relationship between disc degeneration and LBP is a coincidental finding and that the predictive capacity of MRI in terms of LBP is questionable (Boden et al., 1990; Borenstein et al., 2001; Jensen et al., 1994) . However, more recent studies, taking into account specific phenotypes of disc degeneration and based on large populations, have noted a significant association between more moderate and severe forms of degeneration to that of LBP and the predictive capacity of developing more pain severity (Cheung et al., 2009; Samartzis et al., 2011; Takatalo et al., 2011) . Nonetheless, traditional MRI sequences (e.g. T1-or T2-weighted) are not without limitations, as they fail to identify specific biochemical changes of the disc, disease activity and severity of symptoms (Chou et al., 2011; Fenty et al., 2013; Lotz et al., 2012; Zhang et al., 2009) . This may account for some of the tenuous outcomes that accompany spinal fusion procedures or other conservative therapeutics for the disc, the inability to correctly identify early disc changes, and discogenic origins of LBP (Deyo et al., 2005; Fritzell et al., 2002; Rajaee et al., 2011) .
Damage to the disc can induce an inflammatory response involving the production of cytokines and growth factors (Burke et al., 2002; Freemont, 2009) . There is increasing evidence that this inflammatory response is the main pathological reason for the occurrence of discogenic LBP (Wuertz and Haglund, 2013) . Furthermore, damaged discs are also characterised by increased vascularity, facilitating leakage of inflammatory molecules into the circulation. Studies have reported that circulating levels of high-sensitivity C-reactive protein and various interleukins (e.g. IL-6, IL-8) were elevated in patients with chronic LBP and may even serve as markers for prognosticating pain relief (Rannou et al., 2007; Rathod et al., 2014 ; Roy 2 www.ecmjournal.org S Grad et al. Systemic CCL5 and CXCL6 in human disc degeneration et al., 2010) . Moreover, matrix metabolism biomarkers suggest differences in the pathological process of disc space narrowing and osteophyte formation (Goode et al., 2012) . While certain markers of matrix turnover and inflammation are likely to be identical in intervertebral disc and other diseases, there might also be particular molecules that are predominantly released by damaged discs. Therefore, molecular pathological factors associated with disc degeneration may provide additional information to the imaging observations and contribute to better understanding of true discogenic origins of LBP and insights into devising more "precise" and "personalised" therapeutics for the patient . Furthermore, identifying such reliable molecular "biomarkers", for example by blood assessment, may decrease costs associated with expensive imaging, such as MRI, that may also not be readily available in many parts of the world.
Using an in vitro organ culture model, we have shown that mesenchymal stem cell (MSC) homing in induced degenerative discs was mediated by chemoattractants that were released by the damaged disc cells (Illien-Junger et al., 2012) . Further studies revealed that the chemokines C-C motif ligand 5 (CCL5) and C-X-C motif ligand 6 (CXCL6) were released into conditioned medium of induced degenerative discs in organ culture . Interestingly, CCL5 has also been detected in human degenerative disc tissue and appears to play a role in painful disc disorders (Kepler et al., 2013; . Therefore, CCL5 and CXCL6 may be candidate markers to determine the degenerative state of the disc, improve our understanding of discogenic pain subtypes, and potentially monitor patient management/therapeutics. As such, the aim of this study was to compare systemic blood plasma concentrations of CCL5 and CXCL6 in human subjects with no disc degeneration to those with moderate/severe forms of disc degeneration on MRI. We hypothesised that levels of CCL5 and CXCL6 would be elevated in the peripheral blood of patients with disc degeneration compared to physiological levels of subjects without disc changes.
Methods

Study subjects
This was a case-control study whose subjects were sampled from the Hong Kong Disc Degeneration Population-Based Cohort of Southern Chinese Cheung et al., 2010; Samartzis et al., 2012; Samartzis et al., 2011; Song et al., 2008) . This cohort is currently composed of approximately 3,500 volunteer subjects (age range: 10-88 years), who were recruited by open invitation to assess disc degeneration on MRI in congruence with risk factors and clinical profile in association with their degenerative status. None of the subjects were recruited based on their pain phenotype. Institutional review board approval was obtained by each subject enrolled in this study. The recruitment protocol has been previously noted elsewhere and previous studies have shown the cohort to be representative of the population Cheung et al., 2010; Samartzis et al., 2012; Samartzis et al., 2011; Song et al., 2008) .
Imaging assessment
All subjects underwent whole spine T2-weighted sagittal MRI without fat suppression. The MRI protocol was as follows: 5 mm slice thickness, 1 mm slice gap, FOV of 280 mm × 240 mm, and a matrix of 448 × 336. MRIs of the spine were assessed and the discs of the lumbar spine (L1-S1) were graded based on the Schneiderman et al. (1987) radiographic classification for disc degeneration ( Fig. 1a and 1b) . This grading scheme ranged from 0 to 3 and was defined as follows: no degeneration denoted by high signal intensity of the disc (score = 0); mild degeneration with slight decrease in signal intensity of the nucleus pulposus (score = 1); moderate degeneration with generalised hypointensity of the nucleus pulposus (black disc) with normal disc height (score = 2); and severe degeneration (black disc) with disc height narrowing (score = 3). Based on this classification scheme, each of the five lumbar discs was assigned a grade (potential range: 0 to 3). The individual five disc grades were then summated to obtain a global severity of disc degeneration score of the lumbar spine, otherwise known as the Degenerative Disc Disease (DDD) Score (potential score range: 0 to 15). As a secondary phenotype of the disc proper, the presence of lumbar disc displacement was also assessed and noted as any presence of posterior disc bulge, protrusion or extrusion (Fardon et al., 2014) . No sequestration of disc material was noted in this study sample. Furthermore, the presence of cervical disc degeneration, such as decreased disc space height, osteophyte formation, disc herniations, was also noted. Reliability of the scoring protocol has been previously reported and was noted to be excellent (Cheung et al., 2009; . S Grad et al. Systemic CCL5 and CXCL6 in human disc degeneration
Selection of non-degenerated and degenerated groups
Based on previous studies of the DDD score and LBP, it was noted that moderate/severe lumbar disc degeneration (DDD score ≥ 5) was significantly associated with a history of LBP (Cheung et al., 2009; Samartzis et al., 2011; Takatalo et al., 2011) . As such, 40 individuals were selected as cases with no disc degeneration representing the control group (DDD score = 0) and 40 individuals were identified as cases representing the disc degeneration group (DDD score ≥ 5). Since disc degeneration and LBP are multifactorial based on several modifiable and non-modifiable risk factors (Andersson, 1999; Samartzis et al., 2012; Shen et al., 2006) , the cases and controls were matched for sex, age, body mass index (BMI; kg/m 2 ), and workload at the time of MRI and blood extraction. Physical workload was assessed based on the individuals' current occupation history, noted as sedentary (score 0), light (score 1), medium (score 3), heavy (score 4) or very heavy (score 5) for each individual. Furthermore, none of these subjects had current spine fractures, tumours, metabolic disorders, or progressive inflammatory disease.
Blood collection and CCL5/CXCL6 analysis
Around the time of imaging, peripheral blood was collected from each subject. Blood samples were obtained in the morning, and all individuals were fasting and at rest at time of blood collection. Blood was collected in tubes containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant and the tubes were centrifuged for 15 min at 1000 ×g within 30 min of collection. Resulting blood plasma samples were stored at −80 °C. Concentrations of CCL5 and CXCL6 in all plasma samples were quantified in duplicates after appropriate dilution using commercially available ELISA systems (Quantikine, R&D Systems, Minneapolis, MN, USA). Quantitative values for CCL5 and CXCL6 were noted in ng/mL and pg/mL, respectively.
Statistical analysis
All data were obtained and entered upon a spreadsheet. SPSS version 21 (Chicago, IL, USA) was used to conduct descriptive and analytical analyses. Descriptive analyses were performed of all the data points. Chi-square tests were utilised to assess the difference between categorical variables. Independent sample t-tests were utilised to assess the mean difference and 95 % confidence intervals (CI) between the control and degenerative groups with regards to subject characteristics and chemokine levels for continuous variables. Receiver operating characteristic (ROC) curve analyses was also performed to determine the area under the curve (AUC) of chemokine levels to that of lumbar disc degeneration. Power analyses were also conducted based on the mean difference and standard deviations between both CCL5 and CXCL6 in relation to group-type with an alpha value of 0.05. Statistical power of 0.90 or greater was considered excellent (Vavken et al., 2015) . Furthermore, for secondary phenotype analyses, if the data distribution deemed so, multivariate analyses were performed taking into account the covariates of age, sex, BMI and workload. The threshold for statistical significance was established at p < 0.05. Precision was also assessed based on 95 % CI bounds.
Results
Blood plasma concentrations were assessed in all 80 subjects. Each of the groups had 26 females and 14 males (p = 1.000). The mean ages for the control and disc degeneration groups were, 49.2 y (SD: ± 5.8; range: 34.3-58.8 y) and 49.5 y (SD: ± 5.9; range: 34.1-58.5 y), respectively (p = 0.853). The mean BMIs for the control and disc degeneration groups were 23.3 kg/m 2 (SD: ± 2.6; range: 18.2-30.1 kg/m 2 ) and 23.4 kg/m 2 (SD: ± 2.7; range: 18.6-31.3 kg/m 2 ), respectively (p = 0.885). The control group had no disc degeneration (DDD score = 0), whereas the degeneration group had a mean DDD score of 6.6 (SD: ± 2.0; range: 5-12) (p < 0.001). In the disc degeneration group, most of the disc degeneration was noted in the lower lumbar spine (i.e. L4-S1), affecting 95.0 % of the discs. Overall disc displacement was noted only in the disc degeneration group, occurring in 62.5 % of the subjects (n = 25). Cervical disc changes were noted in 32.5 % of the control group compared to 46.2 % in the lumbar disc degeneration group (p = 0.214). Patient characteristics are summarised in Table 1 .
The overall CCL5 and CXCL6 blood plasma concentrations were 16.3 ng/mL (SD: ± 13.0; range: 2.1-63.8 ng/mL) and 50.2 pg/mL (SD: ± 23.5; range: 16.7-150.5 pg/mL), respectively (Table 1) . CCL5 blood plasma concentrations were significantly increased in the disc degeneration group (mean: 19.8 ng/mL; 95 % CI: 14.7-25.0 ng/mL) compared to the control group subjects (mean: 12.8 ng/mL; 95 % CI: 10.3-15.2 ng/mL) (p = 0.015) (Fig. 2a) . Similarly, CXCL6 blood plasma concentrations were significantly higher in the disc degeneration group (mean: 56.9 pg/mL; 95 % CI: 48.5-65.3 pg/mL) compared to the levels of the control group (mean: 43.4 pg/mL; 95 % CI: 37.5-49.3 pg/mL) (p = 0.010) (Fig. 2b) . When focussing at different lumbar levels of the spine from L1-S1, specifically looking at high, mid and lower lumbar regions in individuals with noted degenerated disc changes on MRI, CCL5 and CXCL6 concentrations did not vary between different degenerated levels (L1-S1) of the lumbar spine (p > 0.05). Based on ROC analyses, AUCs for CCL5 and CXCL6 were 0.61 (95 % CI: 0.48-0.74) and 0.67 (0.55-0.78), respectively (Fig. 3) .
With regards to the secondary phenotype of disc displacement noted in the disc degeneration group, no statistically significant difference was noted based on the sample size between the presence or not of disc displacement to that of CXCL6 (p = 0.597); however, a suggestive trend towards significance was noted with elevated levels of CCL5 in subjects with disc displacement (mean: 23.4 vs. 14.0 ng/mL; p = 0.073). All subjects with disc displacement had some degree of disc degeneration. No statistical difference was noted between cervical disc changes and chemokine levels (p > 0.05). Since we did not find any significance in the relation between chemokine levels and cervical disc changes, cases that had cervical changes were not excluded from the overall evaluation. Based on the findings, the statistical powers for the CCL5 and CXCL6 chemokine assessments were considered excellent with values of 0.98 and 0.99, respectively, in relation to assessing the difference between non-disc S Grad et al. Systemic CCL5 and CXCL6 in human disc degeneration degeneration and moderate/severe disc degeneration groups.
Discussion
The results of this study demonstrate for the first time in humans that significantly elevated levels of systemic blood plasma concentrations of distinct chemokines CCL5 and CXCL6 were noted in individuals with moderate/severe disc degeneration in comparison to a control group with no signs of disc degeneration on MRI. Importantly, the study subjects were matched for age, sex, BMI and workload, so that any influence of these parameters on the outcome can be excluded/minimised. Our findings further substantiate our previous work as well as that of others based on animal models and human extracted symptomatic disc tissue that CCL5 and CXCL6 are associated with clinically-relevant degenerated disc. Therefore, systemic CCL5 and CXCL6 levels might be considered as molecular "biomarkers" for the diagnosis and monitoring of clinically-relevant disc disease. Serological analyses have several advantages among diagnostic tools; they are non-invasive, simple, convenient, quantitative and reproducible. In the case of disc degeneration, the quantitative and objective data obtained by serological tests may be valuable for complementing image-based assessments. Conventional imaging reflects a condition of disc-related changes that occurred in the past, while assessment of current activity of the disease is restricted. In contrast, the measurement of circulating biomarkers provides the potential for monitoring disease state, progression or treatment effectiveness.
Potential circadian variations need to be taken into consideration when comparing plasma chemokine levels, although there is limited information available from the literature. A recent study with 30 healthy aging subjects found that blood plasma levels of most inflammatory mediators were increased when the blood was taken in the afternoon compared to samples drawn in the morning (Altara et al., 2015) . While this increase was not significant for CCL5, CXCL6 was not assessed in that study. Nevertheless, the potential of diurnal changes in chemokine levels underlines the importance of a standardised blood sampling protocol as applied in the present study.
A panel of biomarkers has been developed with the potential to monitor severity, activity and progression of arthritic diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA) (Mabey and Honsawek, 2015) . Such markers of matrix breakdown, matrix synthesis, or inflammation are detectable in synovial fluid and in the peripheral blood of patients with acute or chronic disorders of the synovial joint. A recent review of the different cytokines considered as biochemical markers for osteoarthritis revealed IL-6 as a potential diagnostic and prognostic marker, whereas other cytokines such as IL-1β, TNF-α, IL-15 and VEGF were associated with the disease burden (Mabey and Honsawek, 2015) . It has been suggested that inflammatory biomarkers may play a role in identifying subgroups of OA patients with different disease progression rates; this may allow the clinician to differentiate phenotypes within a heterogeneous population and to adjust the treatment accordingly (Attur et al., 2013) .
The inflammatory chemokine CCL5 has been investigated in several studies addressing arthritic diseases. CCL5 is produced by articular chondrocytes, and its Grad et al. Systemic CCL5 and CXCL6 in human disc degeneration production can be up-regulated by the pro-inflammatory cytokines IL-1 and TNF-α . Progressive RA has been associated with increased serum values of CCL5, while serum CCL5 was responsive to methotrexate treatment (Boiardi et al., 1999) . Specific histological variants of synovitis have been correlated with varying serum concentrations of CCL5 in RA patients and could reflect the clinical activity of the disease (Klimiuk et al., 2005) . Torikai et al. (2007) also reported that CCL5 serum levels were significantly increased in RA patients compared with normal volunteers, although treatment with anti-inflammatory infliximab did not affect CCL5 concentration. Furthermore, active but not inactive state of OA was associated with elevated serum levels of TNF-α, IL-6 and CCL5 (Toncheva et al., 2009 ). More recently, CCL5 has been recognised as a chemotactic mediator produced by intervertebral disc cells. In an organ culture model, this chemokine has been identified as a key factor mediating stem cell recruitment in induced degenerative discs . Kepler et al. (2013) found increased expression of CCL5 in painful disc disease, whereby its expression was enhanced with increasing disc degeneration grade. Moreover, CCL5 expression was correlated with increased levels of the inflammatory cytokine IL-1β and could be induced by IL-1β and TNF-α in vitro (Gruber et al., 2014; Kepler et al., 2013) . Histological observations further corroborated the presence of this chemokine in human intervertebral discs (Gruber et al., 2014; Pattappa et al., 2014) . In a cohort of older adults with LBP, a correlation was found Fig. 2 . Error bars illustrating means and 95 % confidence levels of systemic blood plasma concentrations of (a) CCL5 (ng/ mL) and (b) CXCL6 (pg/mL) in patients with no disc degeneration (control group) and those with disc degeneration (degenerated group). p = 0.015 (a) and p = 0.010 (b) denote statistical significant difference.
Control
S Grad et al. Systemic CCL5 and CXCL6 in human disc degeneration Fig. 3 . Receiver operating characteristics curve noting the area under the curve for CCL5 and CXCL6 in relation to the presence of disc degeneration.
between pain and pain-related functions and circulating concentrations of CCL5 (Sowa et al., 2014) . It was concluded that this biomarker may be used for assessment of the disease state in older adults, where imaging changes are omnipresent (Sowa et al., 2014) . The present study adds to these previous observations the important finding of a demarcation in plasma levels between subjects with disc degeneration and non-degenerative matched control subjects. Systemic CCL5 values exceeding a certain physiological concentration may thus also contribute to the diagnosis of a degenerative disc state in patients younger than 60 years. Furthermore, the present study revealed a trend towards higher CCL5 levels in DDD patients with disc displacement compared to DDD patients without disc displacement. This observation is further supported by the increased chemokine levels often associated with structural and morphological disc alterations. The chemokine CXCL6, also known as granulocyte chemotactic protein 2 (GCP2), has been less intensely investigated. Among a panel of various cytokines and chemokines, CXCL6 can be induced in chondrocytes in response to IL-1β (Sandell et al., 2008) . CXCL6 has been identified, in addition to CCL5, in fibroblast cells of RA patients and is significantly up-regulated by tolllike receptor stimulation (Pierer et al., 2004) . In OA chondrocytes, IL-1 mediated expression of CXCL6 can be suppressed by the polyphenol epigallocatechin-3-gallate, demonstrating its responsiveness to anti-inflammatory treatment (Akhtar and Haqqi, 2011) . CXCL6 has been detected in conditioned medium of intervertebral discs in organ culture and may contribute to the chemotactic response of induced-degenerative discs . The finding of elevated circulating levels of CXCL6 in patients with disc degeneration is novel and may lead to more specific diagnostic possibilities in the area of disc diseases. Furthermore, in our current study, CXCL6 seems to be slightly more predictive or associated with moderate/ severe disc degeneration that CCL5 as noted by the ROC analyses.
It has been reported that human NP and AF tissues as well as human organ cultured whole degenerative discs release CCL5 (Krock et al., 2014; Li et al., 2005) ; while CCL5 and CXCL6 were secreted by induced degenerative whole discs with endplates . We therefore hypothesise that in moderately to severely degenerative lumbar discs these chemokines actively diffuse through the endplate and the annulus fibrosus, along with an increased nerve and vessel ingrowth in degenerative discs (Krock et al., 2014) . Through this mechanism increased amounts of cytokines may be detectable in the circulation even if they arise from a nonvascularised tissue. Furthermore, CCL5 and CXCL6 were also detected in the blood plasma of subjects with no disc degeneration. This is consistent with the physiological functions of these cytokines as chemotactic and activating factors of immune cells, further stressing their major roles in immune responses.
Naturally, there were some limitations associated with this study. Although we noted elevated chemokine levels in individuals with moderate/severe lumbar disc degeneration, it remains unknown if indeed these levels represent activity in the discs or active inflammation in peripheral regions of the body. Nonetheless, from our understanding, we did not note any evidence that subjects may have coexisting conditions that may confound the sensitivity of the biomarkers in this setting and in addition did not seem to be related to the presence of disc degeneration in other spine regions. Furthermore, we attempted to account for all potential co-morbidities at the time of recruitment. The prevalence of reported co-morbidities in our study sample was not prominent, because these were volunteer individuals from the population and not patient-based, S Grad et al. Systemic CCL5 and CXCL6 in human disc degeneration whereby a higher prevalence of co-morbidities would exist. Furthermore, our understanding of these biomarkers is still relatively new. We hope that our current study, which is the first to find an association between systematic biomarkers and stages of disc degeneration on MRI, would provide further credence for future studies to assess extraneous factors that may affect these chemokines in relation to spine degeneration. Also, although our AUC values were not relatively high in relation to disc degeneration, this may be influenced by the range of degenerative scores, the phenotype sensitivity of disc degeneration on traditional T2W MRI, sample size, and the fact that our cohort samples were drawn from the population and were not patient-based that typically may present with extensive disc changes. Nonetheless, it is not uncommon for even other clinical biomarkers in current clinical use, such as those used to detect prostate and bladder cancer among others, to have similar AUC values (Glas et al., 2003) . Importantly, our findings that systemic blood levels of CCL5 and CXCL6 were significantly elevated in subjects with disc degeneration further support our previous work (Illien-Junger et al., 2012; and that of others (Kepler et al., 2013) noting similar chemokine changes in human degenerated disc tissue. Furthermore, we employed a case-control approach whereby both groups were matched for modifiable and non-modifiable risk factors to allow direct comparisons of the chemokine levels between groups. Although the sample size in each group was modest, excellent statistical power calculations were noted. Moreover, our subjects represent a homogenous population and ethnic variations may exist that may affect the generalisability of the findings. However, such homogeneity is an advantage in this case to avoid potential confounding with ethnicity in studies. That said, our findings provide the foundation that systemic blood chemokine levels may exist that are implicated with clinically-relevant disc degeneration but require further replication in other ethnic cohorts. Future large, prospective studies are further needed to assess the clinical utility of these biomarkers and their influence upon clinical decision-making.
Conclusions
Our study is the first to note in humans that elevated systemic blood plasma levels of CCL5 and CXCL6 are associated with moderate/severe lumbar disc degeneration on MRI. These chemokines might provide valuable information about the degenerative state of an intervertebral disc in addition to structural/morphological findings observed on imaging. Moreover, the findings further contribute to our understanding of the degenerative process, and may eventually lead to new diagnostic and therapeutic options. Further studies will be required to assess the validity of systemic CCL5 and CXCL6 levels for identifying discogenic related LBP, monitoring disease progression and/or treatment effects, as well as for replication in other populations.
